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Abstract
Purpose—Previous studies have shown an association between maternal fever in early pregnancy 
and neural tube defects (NTDs) such as spina bifida. Periconceptional folic acid intake has been 
shown to reduce the risk of these outcomes.
Methods—Using data from the Slone Epidemiology Center Birth Defects Study (1998–2015), 
we examined the impact of folic acid on the relationship between maternal fever in the 
periconceptional period (28 days before and after the last menstrual period) and NTDs. Logistic 
regression models were used to calculate adjusted odds ratios (ORs) and 95% confidence intervals 
(CIs).
Results—Mothers of 375 cases and 8247 nonmalformed controls were included. We observed an 
elevated risk for NTDs for fever in the periconceptional period (OR: 2.4; 95% CI: 1.5–4.0). This 
association was weaker for mothers who reported consuming the recommended amount of folic 
acid (≥ 400 μg per day; OR: 1.8; 95% CI: 0.8–4.0) than mothers with low folic acid intake (<400 
μg per day; OR: 4.2; 95% CI: 2.2–8.2).
Conclusions—Our data support an association between maternal periconceptional fever and an 
increased risk for NTDs and also provide evidence that this association was attenuated for mothers 
who reported consuming folic acid at recommended levels in the periconceptional period.
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Introduction
Neural tube defects (NTDs) are severe malformations of the central nervous system that can 
be incompatible with life or cause lifelong disability. NTDs are estimated to affect 7 of 
10,000 pregnancies in the United States annually [1]. Based on epidemiologic evidence 
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showing that daily intakes of at least 400 μg of folic acid reduced NTD risk [2], fortification 
of cereal grain supplies in the United States and Canada began in 1998, which aimed to 
deliver, on average, this amount of folic acid to 90% of the childbearing aged women [3,4]. 
Since 1998, the prevalence of NTDs has decreased substantially, but the target for folic acid 
intake has not been met, and NTD cases continue to occur [1,5]. Thus, continued research is 
warranted to identify other risk factors for NTDs and to determine whether folic acid intake 
modifies the effects of these factors.
Maternal hyperthermia in early pregnancy has been identified as a risk factor for NTDs in 
both animal and human studies [6–8], but it is not clear if folic acid intake modifies the risk. 
Heat-induced NTDs in mice were less prevalent among those with folic acid exposure 
compared to those unexposed [9]. Similarly, three studies of febrile illness in pregnant 
women reported lower NTD risks among those using folic acid supplements or 
multivitamins in early pregnancy compared to those not supplementing [10–12]. However, 
one of these studies relied on a relatively small sample size [10], and all took place outside 
the context of folic acid fortification [10–12]. In addition, many studies of maternal fever are 
limited by a broad exposure definition and lack detail on hyperthermia timing and the role of 
antipyretic treatment. These limitations were addressed in the present analysis of data 
collected by the Slone Epidemiology Center Birth Defects Study (BDS).
Materials and methods
Study population
The BDS is a case-control study that recruited mothers from 1976 to 2015, whose 
pregnancies were or were not affected with a malformation. The current analysis is limited 
to NTD cases and nonmalformed controls born between 1998 and 2015, when cereal grains 
were fortified with folic acid in the United States and Canada. The methods have been 
described in detail previously [13,14]. For this analysis, infants, fetuses, and stillbirths with 
any major structural malformations (cases) were ascertained at participating hospitals or 
birth defect registries for parts of Massachusetts, areas surrounding Philadelphia, PA; San 
Diego, CA (since 2001); Toronto, Canada (until 2005); Nashville, TN (since 2012); and 
parts of New York State (since 2004). Control subjects were live-born infants who were 
ascertained from study hospitals and birth certificates in the catchment areas from which 
cases were recruited.
Within 6 months of delivery, mothers were invited to participate in a computer-assisted 
telephone interview conducted by trained study nurses. Subjects were asked about 
demographic factors, reproductive history, behaviors such as alcohol and tobacco use during 
pregnancy, as well as dietary patterns in the 6 months before pregnancy. Data were recorded 
on illness history and medications used during the 2 months before the last menstrual period 
(LMP) to the end of pregnancy. Medication data included information on use of prescription 
drugs, vaccines, over-the-counter medications, dietary supplements, and vitamin products. 
Detailed information on timing of illness and medication use was collected to relate 
exposures to developmental time periods of interest during pregnancy. Participation rates for 
cases and controls were 64% and 60%, respectively. This study has been approved by the 
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institutional review boards of Boston University Medical Center and relevant participating 
institutions.
Measurements
Outcomes—For this analysis, NTD outcomes were examined as a group and included 
spina bifida, anencephaly, and encephalocele. Cases were categorized as multiple or isolated, 
with isolated cases having no other major defect diagnoses except those considered 
secondary to the NTD (e.g., clubfoot, hydrocephaly, and hip dislocation). NTD cases were 
excluded if they had an additional diagnosis of a chromosomal abnormality, Mendelian 
inheritance disorder, known syndrome, amniotic bands, body wall defect, or conjoined twin.
Exposure definitions—Mothers were asked if they experienced any of the following 
illnesses: fever alone, chicken pox, urinary tract infection, stomach virus/stomach bug, cold, 
flu, cough, bronchitis, pneumonia, sinus infection, congestion, flu-like illness, ear infection, 
strep throat, tooth abscess, and asthma with cold; if so, start and stop dates and details on 
type and timing of medication use were recorded. They were also asked if a fever 
accompanied the illness, and if so, whether the temperature of the fever was greater than or 
equal to 101°F. Dates of fever were not asked separately from the dates of illness.
For fever and other exposures, we defined the periconceptional period as the 2 lunar months 
beginning 28 days before the LMP and ending 28 days after the LMP. Any report of a fever 
during this interval was considered an exposure. We excluded women who reported fever 
only outside the periconceptional time period (75 cases, 1927 controls) or with unclear 
timing (3 cases, 95 controls). The unexposed referent group is therefore women who did not 
report fever from 2 months before the LMP until the end of pregnancy. Subgroups of fever-
exposed women included those defined by reported temperature level (≥ 101°F, <101°, or 
undocumented) and antipyretic treatment (acetaminophen, aspirin, other nonsteroidal 
antiinflammatory drugs) of the reported fever.
Folic acid intake—Total periconceptional folic acid intake was calculated by combining 
the average daily synthetic folic acid intake from fortified foods and from supplements. 
Naturally occurring food folate was included but discounted by 30% because of its lower 
bioavailability [15]. Diet information was ascertained using an adapted Willett food 
frequency questionnaire (FFQ) focused on the 6 months before pregnancy, to reflect diet in 
the earliest stages of gestation when pregnancy might not yet be recognized. After 
calculating an average daily exposure amount from the FFQ, we adjusted these values for 
total caloric intake using the residual method [16]. We then added this value to the reported 
intake from supplements. Women who reported extreme caloric intake (<500 or >4000 kcal 
per day) were excluded (n = 88, 1% of subjects). Our primary folic acid intake variable was 
created by dichotomizing average daily exposure at the recommended intake level of greater 
than or equal to 400 μg per day, with intake of at least 400 μg per day considered to be 
“adequate” for NTD prevention. Women with missing FFQ data were included and 
categorized as having adequate folic acid intake if they reported vitamin supplementation 
greater than or equal to 400 μg per day (n = 246, 3% of subjects), or categorized as having a 
folic acid intake of less than 400 μg per day if they reported no vitamin intake (n = 524, 6% 
Kerr et al. Page 3
Ann Epidemiol. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of subjects), because it is unlikely these women would achieve greater than or equal to 400 
μg per day from diet alone [5]. Women with missing FFQ data were excluded if reported 
folic acid intake from vitamin supplementation was less than 400 μg per day, because they 
may or may not have reached 400 μg per day depending on diet (n = 103, 1% of subjects). In 
addition, less than 1% of subjects completed the FFQ with less than 400 μg per day but were 
excluded due to incomplete or unknown supplement data (n = 30).
Statistical analyses
We used logistic regression models to calculate crude and adjusted odds ratios (ORs) and 
95% confidence intervals (CIs) for the association between reported periconceptional fever 
and fever subgroups with NTDs. The distribution of demographic and maternal health 
characteristics for cases and controls and by reported periconceptional fever among controls 
only was calculated. These characteristics were also evaluated as potential confounders and 
were maternal age (categorized <20, 20–24, 25–29, 30–34, 35–39, and 40 + years), maternal 
education (<high school, high school graduate or equivalent, and greater than high school), 
maternal race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and other), 
study center, category of body mass index (kg/m2; <18.5, 18.5–24.9, 25–29.9, and ≥30) [17], 
LMP year, and folic acid intake (<400 μg per day, ≥400 μg per day). We also considered any 
reported antipyretic medication exposure, the majority of which did not accompany fever, 
and periconceptional illnesses without fever as potential confounders because each could be 
independently associated with NTD risk. Variables that changed ORs by 10% or more were 
included in adjusted models.
We analyzed the joint effect between folic acid intake and reported fever on NTD risk by 
categorizing subjects into four groups: (1) greater than or equal to 400 μg per day of folic 
acid without fever (referent), (2) less than 400 μg per day of folic acid without fever, (3) 
greater than or equal to 400 μg per day of folic acid and fever, and (4) less than 400 μg per 
day of folic acid and fever and calculating the relative excess risk due to interaction (RERI) 
[18]. The RERI is a measure that can be used to assess whether the joint effect of fever and 
folic acid intake less than 400 μg per day is greater than would be expected, given the 
individual additive effects.
In a sensitivity analysis, we excluded subjects with any of the following established risk 
factors for NTDs: periconceptional exposure to antiepileptic drugs, family history of NTDs, 
and pre-existing diabetes. We also conducted sensitivity analyses in which we limited the 
case group to those with isolated NTDs and to those with just spina bifida. Finally, we 
performed an analysis in which we included in the unexposed group women whose fever 
was reported to have occurred in lunar month 3 or later. (These women were excluded from 
the primary analysis.) All analyses were conducted in SAS 9.4 (SAS Institute, Inc., Cary, 
NC).
Results
A total of 453 NTD cases and 10,269 nonmalformed controls were available for analysis. 
We excluded 78 cases (17.2%) and 2022 controls (19.7%) who reported fever outside the 
periconceptional period or fever with unclear timing, resulting in a final study population of 
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375 cases and 8247 controls. Compared to controls, mothers of cases were more likely to be 
younger (<30 years old), non-Hispanic black or Hispanic, overweight, or obese, to report 
periconceptional illness without fever and to have LMP during 2003–2008; mothers of cases 
were less likely to have education beyond high school or to meet the recommended folic 
acid intake; no notable differences in prevalence of antipyretic use in the periconceptional 
period were noted. Differences between cases and controls were also observed for study 
center (Table 1).
Among controls, mothers who reported periconceptional fever (n = 154) were more likely to 
have education beyond high school, be non-Hispanic white, have their LMP in the earlier 
years of the study (1997–2002), and have greater than or equal to 400 μg of folic acid intake 
per day, compared to mothers who did not report periconceptional fever (n = 8093) (Table 
1). Antipyretic medication use, for any indication, was more common in control mothers 
with periconceptional fever than among those without fever (60.4% compared to 32.3%).
Mothers of NTD cases reported periconceptional fever more commonly (5.1%, n = 19) than 
mothers of control infants (1.9%, n = 154; Table 2). Of these 19 NTD cases, 16 were spina 
bifida cases and three were anencephaly or encephalocele. The adjusted OR for any 
periconceptional fever was 2.4 (95% CI: 1.5–4.0). Study center was the only covariate that 
met the criterion for confounding and was therefore included in adjusted models. Among 
those mothers reporting periconceptional fever, 31.6% of case mothers (n = 6) and 40.3% of 
control mothers (n = 62) had a reported temperature of at least 101°F; information on fever 
temperature was missing for 4 case mothers (21.1% of those reporting fever) and 30 control 
mothers (19.5% of those reporting fever). Compared to mothers without fever, the adjusted 
OR for fevers of greater than or equal to 101°F was 2.1 (95% CI: 0.9–5.1), and for fevers of 
less than 101°F, the OR was 3.3 (95% CI: 1.6–6.9). Overall, the adjusted ORs stratified by 
use of antipyretic treatment were similar: 2.2 (95% CI: 1.0–4.9) for women who reported the 
use of antipyretics and 2.6 (95% CI: 1.4–5.0) for women who did not report the use of 
antipyretics. When the analysis considered the joint effects of reported temperature and 
antipyretic treatment, adjusted ORs were not higher for mothers with high fevers but were 
higher among mothers who reported using no antipyretic treatment than among mothers who 
reported using these medications within both the lower and higher temperature groups. 
However, numbers of cases in the joint effects analysis were quite small and 95% confidence 
intervals overlap considerably.
Overall, the 2.4-fold increased risk for NTDs among mothers with periconceptional fever 
appeared to be modified by folic acid intake. Among mothers who did not consume folic 
acid in amounts considered “adequate” for NTD prevention, the adjusted OR for 
periconceptional fever was 3.4 (95% CI: 1.8–6.6), whereas the adjusted OR for mothers 
whose intake was “adequate” was 1.8 (95% CI: 0.8–4.0) (Table 3). Mothers reporting both 
periconceptional fever and less than 400 μg per day of folic acid intake had an adjusted OR 
of 4.2 (95% CI: 2.2–8.2) compared to the reference group of mothers without fever and with 
greater than or equal to 400 μg per day of folic acid intake (Table 3). This association is 
larger than that would be expected due to independent additive effects of inadequate folic 
acid intake and periconceptional fever (RERI = 2.2 [95% CI: −0.9 to 5.3]).
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Findings did not appreciably change in the four sensitivity analyses: (1) exclusion of the 28 
cases and 203 controls with exposure to antiepileptic drugs, family history of NTDs or pre-
existing diabetes, (2) exclusion of the 76 nonisolated cases, and (3) restriction to spina bifida 
cases only (Supplementary Table). We also performed a sensitivity analysis (4) including as 
unexposed those mothers whose only fever was later in pregnancy (lunar month 3 through 
end of pregnancy); the adjusted OR for fever increased slightly to 2.6 (1.5–4.2) (data not 
shown).
Discussion
The results of this analysis support previous findings of an increased risk for NTDs in 
offspring born to mothers who report maternal fever in early pregnancy. We observed a 2.4 
times greater risk for having an NTD-affected pregnancy among mothers reporting a fever in 
the month before or the month after LMP compared to mothers who reported no fevers 
during pregnancy. This association was similar after the exclusion of women with known 
risk factors for NTDs, including family history of NTDs, lending further support for a true 
association.
A 2005 meta-analysis of maternal hyperthermia and NTDs reported an overall OR of 1.9 
(95% CI: 1.6–2.3) [8], which was lower than our observed 2.4-fold OR (95% CI: 1.5–4.0) 
and perhaps due to differences in exposure windows. Many previous studies examined fever 
in the first trimester, but our exposure window was the narrower 56-day period surrounding 
the LMP because NTDs develop shortly after conception. Fevers later in the first trimester 
should not influence the risk of NTDs, and the resulting misclassification would likely 
attenuate a true association. In addition, we were able to consider the risk associated with the 
level of reported temperature. Risk estimates for women reporting higher temperatures 
(≥101°F) were not greater than those reporting lower temperatures providing no evidence of 
a dose response, although our sample was small and estimates were therefore unstable. Our 
findings are similar to those of 2 previous reports of an increased NTD risk for fever in the 
first trimester that was attenuated but not eliminated by antipyretic medication treatment 
[19,20]. Although our observed NTD risks did not appear to be related to the temperature of 
the reported fever, antipyretic treatment appeared to reduce the NTD risk, whether the fever 
was high or low.
Our data showed that average intake of at least 400 μg per day of folic acid was associated 
with an attenuated, although still elevated, odds of having an NTD-affected pregnancy 
among women who reported periconceptional fever. Three previous studies also showed 
higher ORs for women with fever who did not take vitamin supplements [10–12], although 
two of them were based on very small numbers [10,11]. Another study observed an 11-fold 
increased NTD risk for women with early pregnancy fever and a variant of the folate carrier 
gene SLC19A1 [21]; however, folic acid exposure was not examined.
The mechanism by which fever might affect development of the neural tube is not known, 
nor has the pathway between folate deficiency and NTDs been well delineated. Animal 
studies suggest that hyperthermia-induced NTDs are caused by apoptosis of neurons, and 
folic acid has been hypothesized to reduce abnormal cell death in the developing fetus 
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[9,22]. It is also worth noting that many women are exposed to folic acid through 
multivitamins, which contain myriad other vitamins and minerals; high folic acid–diets 
similarly include other vitamins and minerals [23]. Thus, we cannot exclude the possibility 
that the reduction of fever-associated NTD risk associated with folic acid intake may be due 
to confounding by intake of other nutrients.
Strengths of this study include our ability to identify exposures with greater detail than many 
previous studies [10,12,24], including the availability of information on fever temperature, 
average daily folic acid intake, and medication use. By including information on both dietary 
and supplemental folic acid, we were able to better estimate total folic acid intake to observe 
biologically plausible interactions. Another strength of the study is the short interval 
between the time of birth and data collection (maximum of 6 months), which likely 
improves recall accuracy. Nevertheless, retrospective reporting of exposures may have led to 
misclassification. We assumed that the timing of fever and antipyretic treatment was the 
same as that reported for the accompanying illness, which may not be the case. For fevers 
reported in the absence of illness, this assumption was not necessary. Whether reporting 
errors would be more common in cases than controls is not clear, but it is important to 
consider possible under-reporting by controls compared to cases (i.e., recall bias). Although 
we have no direct way to assess whether such a bias exists, it is of note that the proportions 
of fevers with undocumented temperature were similar for cases and controls (21% and 
19%, respectively). Another possible source of under-reporting of fever is the fact that the 
interview did not specifically ask about fever accompanying sexually transmitted or vaginal 
infections. However, the prevalence of these illnesses in the periconceptional period was 
higher in NTD cases (4.5%) than that in the controls (1.1%); thus, under-ascertainment of 
fever due to these illnesses would likely have biased our results toward the null. Other 
potential limitations include the limited number of NTD cases with fever (n = 19) and 
minimal variability by phenotype (all but three NTD cases with fever were spina bifida 
cases).
In summary, we observed an elevated risk for NTDs for mothers reporting periconceptional 
fever, but this association was lower among mothers who consumed at least 400 μg per day 
of folic acid. Antipyretic treatment of fever also appeared to mildly attenuate NTD risk. It is 
difficult to prevent fever in pregnancy; although symptoms may be relieved by antipyretics, 
daily intake of 400 μg of folic acid among women of childbearing ages appears to be 
particularly important for pregnant women experiencing fever. Thus, following the 
recommended intake of at least 400 μg per day of folic acid among women capable of 
becoming pregnant may not only help reduce the risk of NTDs overall but may also reduce 
the risk of NTDs associated with fever. Reaching this level of intake is difficult by diet 
alone; folic acid supplementation is a more efficient and easier means to achieve the 
recommended level [25].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Characteristics of mothers of neural tube defect cases and controls, Birth Defects Study, 1998–2015
Characteristic
NTD cases (n = 
375)
Controls (n = 
8247)
Controls only
Reported 
periconceptional fever 
(n = 154)
No reported fever 
during pregnancy 
(n = 8093)
N (%) N (%) N (%) N (%)
Maternal age (years)
 <20     33 (8.8)   591 (7.2)       7 (4.5)   584 (7.2)
 20–24     66 (17.6) 1232 (14.9)     21 (13.6) 1211 (15.0)
 25–29   113 (30.1) 2203 (26.7)     47 (30.5) 2156 (26.6)
 30–34   103 (27.5) 2710 (32.9)     48 (31.2) 2662 (32.9)
 35–39     54 (14.4) 1270 (15.4)     24 (15.6) 1246 (15.4)
 40+       6 (1.6)   220 (2.7)       6 (3.9)   214 (2.6)
 Unknown       0 (0.0)     21 (0.3)       1 (0.6)     20 (0.2)
Maternal education
 < High school     59 (15.7)   793 (9.6)       7 (4.5)   786 (9.7)
 High school     89 (23.7) 1614 (19.6)     19 (12.3) 1595 (19.7)
 > High school   226 (60.3) 5830 (70.7)   128 (83.1) 5702 (70.5)
 Missing       1 (0.3)     10 (0.1)       0 (0.0)     10 (0.1)
Maternal race/ethnicity
 Non-Hispanic white   211 (56.3) 5326 (64.6)   115 (74.7) 5211 (64.4)
 Non-Hispanic black     51 (13.6)   726 (8.8)       8 (5.2)   718 (8.9)
 Hispanic     78 (20.8) 1428 (17.3)     12 (7.8) 1416 (17.5)
 Other     35 (9.3)   751 (9.1)     18 (11.7)   733 (9.1)
 Missing       0 (0.0)     16 (0.2)       1 (0.6)     15 (0.2)
Study center
 Massachusetts     59 (15.7) 3990 (48.4)     69 (44.8) 3921 (48.4)
 Philadelphia   108 (28.8) 1516 (18.4)     32 (20.8) 1484 (18.3)
 Toronto     83 (22.1)   483 (5.9)     17 (11.0)   466 (5.8)
 San Diego     66 (17.6) 1338 (16.2)     21 (13.6) 1317 (16.3)
 New York     50 (13.3)   828 (10.0)     14 (9.1)   814 (10.1)
 Nashville       9 (2.4)     92 (1.1)       1 (0.6)     91 (1.1)
Body mass index (kg/m2)
 Underweight (<18.5)     17 (4.5)   345 (4.2)       4 (2.6)   341 (4.2)
 Normal weight (18.5–24.9)   178 (47.5) 4914 (59.6)     93 (60.4) 4821 (59.6)
 Overweight (25.0–29.9)     93 (24.8) 1676 (20.3)     38 (24.7) 1638 (20.2)
 Obese (30+)     68 (18.1) 1076 (13.0)     18 (11.7) 1058 (13.1)
 Missing     19 (5.1)   236 (2.9)       1 (0.6)   235 (2.9)
Year of last menstrual period
 1997–2002   133 (35.5) 3296 (40.0)     77 (50.0) 3219 (39.8)
 2003–2008   112 (29.9) 1878 (22.8)     40 (26.0) 1838 (22.7)
 2009–2014   130 (34.7) 3073 (37.3)     37 (24.0) 3036 (37.5)
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Characteristic
NTD cases (n = 
375)
Controls (n = 
8247)
Controls only
Reported 
periconceptional fever 
(n = 154)
No reported fever 
during pregnancy 
(n = 8093)
N (%) N (%) N (%) N (%)
Periconceptional* folic acid†
 ≥400 mcg   165 (44.0) 4247 (51.5)     89 (57.8) 4158 (51.4)
 <400 mcg   195 (52.0) 3794 (46.0)     63 (40.9) 3731 (46.1)
 Missing     15 (4.0)   206 (2.5)       2 (1.3)   204 (2.5)
Periconceptional* antipyretic use
 Yes   124 (33.1) 2703 (32.8)     93 (60.4) 2610 (32.3)
 No   176 (46.9) 3889 (47.2)     34 (22.1) 3855 (47.6)
 Uncertain     75 (20.0) 1655 (20.1)     27 (17.5) 1628 (20.1)
Periconceptional* illness, without reported 
fever
 Yes     30 (8.0)   475 (5.8)     12 (7.8)   463 (5.7)
 No   345 (92.0) 7772 (94.2)   142 (92.2) 7630 (94.3)
*
Defined as the 28 days before to the 28 days after the last menstrual period.
†Average daily folic acid intake from supplements and diet in the periconceptional period.
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Table 2
Reported maternal fever, fever severity, and the use of antipyretic medication during the periconceptional 
period* and risk for neural tube defects, Birth Defects Study, 1998–2015
Characteristic NTD case
(total = 375)
Control
(total = 8247)
Crude OR
(95% CI) Adjusted OR
†
(95% CI)
N (%) N (%)
Maternal periconceptional fever reported
 Yes   19 (5.1)   154 (1.9) 2.8 (1.7–4.6) 2.4 (1.5–4.0)
 No 356 (94.9) 8093 (98.1) 1.0 (Reference) 1.0 (Reference)
Reported temperature of fever
 ≥101°F     6 (1.6)     62 (0.8) 2.2 (0.9–5.1) 2.1 (0.9–5.1)
 <101°F     9 (2.4)     62 (0.8) 3.3 (1.6–6.7) 3.3 (1.6–6.9)
 Not reported     4 (1.1)     30 (0.4) – –
Antipyretic treatment of reported fever
 Yes     8 (2.1)     62 (0.8) 2.9 (1.4–6.2) 2.2 (1.0–4.9)
 No   11 (2.9)     91 (1.1) 2.8 (1.5–5.2) 2.6(1.4–5.0)
Combination of reported temperature and use of antipyretic treatment for fever
 ≥101°F
  Antipyretic treatment     2 (0.5)     27 (0.3) 1.7 (0.2–6.8) 1.4 (0.2–6.2)
  No antipyretic treatment     4 (1.1)     34 (0.4) 2.7 (0.7–7.6) 2.9 (0.7–8.5)
 < 101°F
  Antipyretic treatment     3 (0.8)     26 (0.3) 2.6 (0.5–8.6) 2.2 (0.4–7.8)
  No antipyretic treatment     6 (1.6)     36 (0.4) 3.8 (1.6–9.1) 4.2 (1.7–10.4)
*
Defined as the 28 days before to the 28 days after last menstrual period.
†Adjusted for Study Center.
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